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ABSTRACT
Objectives To analyse the current evidence for the
management of lupus nephritis (LN) informing the 2019
update of the EULAR/European Renal Association-European
Dialysis and Transplant Association recommendations.
Methods According to the EULAR standardised operating
procedures, a PubMed systematic literature review was
performed, from January 1, 2012 to December 31, 2018. Since
thiswas an update of the 2012 recommendations, the final level
of evidence (LoE) and grading of recommendations considered
the total body of evidence, including literature prior to 2012.
Results We identified 387 relevant articles. High-quality
randomised evidence supports the use of immunosuppressive
treatment for class III and class IV LN (LoE 1a), and moderate-
level evidence supports the use of immunosuppressive
treatment for pure class V LN with nephrotic-range proteinuria
(LoE 2b). Treatment should aim for at least 25% reduction in
proteinuria at 3 months, 50% at 6 months and complete renal
response (<500–700mg/day) at 12months (LoE 2a-2b). High-
quality evidence supports the use of mycophenolate mofetil/
mycophenolic acid (MMF/MPA) or low-dose intravenous
cyclophosphamide (CY) as initial treatment of active class III/IV
LN (LoE 1a). Combination of tacrolimus with MMF/MPA and
high-dose CY are alternatives in specific circumstances (LoE
1a). There is low-quality level evidence to guide optimal
duration of immunosuppression in LN (LoE 3). In end-stage
kidney disease, all methods of kidney replacement treatment
can be used, with transplantation having the most favourable
outcomes (LoE 2b).
Conclusions There is high-quality evidence to guide the
initial and subsequent phases of class III/IV LN treatment,
but low-to-moderate quality evidence to guide treatment of
class V LN, monitoring and optimal duration of
immunosuppression.
INTRODUCTION
Lupus nephritis (LN) affects a significant pro-
portion of patients with systemic lupus erythe-
matosus (SLE) and is accompanied by
significant morbidity.1 To facilitate physician
decisions and homogenise patient care, the
first set of joint EULAR/European Renal
Association-European Dialysis and Transplant
Association (ERA-EDTA) recommendations
for the management of LN was published in
2012.2 Since then, a number of randomised
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What is already known about this subject?
► Recently, the updated EULAR/ERA-EDTA recomm
endations for the management of lupus nephritis were
published, following a systematic literature review of 15
research questions. The present study outlines the
methodology and results of this systematic review.
What does this study add?
► A response in proteinuria within 12months is the most
valuable parameter to predict a favourable long-term
outcome in lupus nephritis. Treatment should aim for
at least 25% reduction in proteinuria at 3 months,
50% at 6 months and complete renal response
(<500–700 mg/day) at 12 months.
► High-quality evidence supports the use of mycop
henolate mofetil/mycophenolic acid or low-dose
intravenous cyclophosphamide as initial treatment of
active class III/IV lupus nephritis.
► Despite the paucity of randomised controlled trials,
the recommendation for a lower cumulative
glucocorticoid dose adapts to the current trend in
SLE therapeutics, towards rationalisation of
glucocorticoid use.
How might this impact on clinical practice?
► The updated recommendations will help guide
physicians caring for patients with lupus nephritis
and the results of this systematic review will serve
as evidence base for further future updates.
Lupus
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controlled trials (RCTs) have been conducted and meta-
analyses of different treatments have been published,
while a number of issues regarding optimal monitoring
of LN, duration of immunosuppressive treatment and
management of end-stage kidney disease (ESKD) are
still a matter of debate. To this end, an update of the
2012 recommendations was recently published,3 with
the participation of a multidisciplinary Task Force.
Here, we report the results of the systematic literature
review (SLR) which informed the 2019 update of the
EULAR/ERA-EDTA recommendations for the manage-
ment of LN. These were presented to the Task Force
during a dedicated meeting, to provide the current evi-
dence base and facilitate the formulation of overarching
principles and individual recommendations.
METHODS
We followed the standardised operating procedures for the
development of EULAR-endorsed recommendations and
employed the Appraisal of Guidelines Research and Evalua-
tion instrument.4 A Delphi-based methodology within the
Task Force identified 15 research questions covering the
following topics related to LN: diagnosis and classification,
pharmacologic treatment, monitoring and therapeutic tar-
gets, refractory LN, management of LN in pregnancy, anti-
phospholipid syndrome-associated nephropathy, chronic
kidney disease, comorbidities and adjunctive therapy.
Since this was an update of the 2012 recommendations,
the SLR considered all PubMed English-language articles
published between January 1, 2012 andDecember 31, 2018.
As the search strategy intended to address 15 different
questions, instead of performing a single, broad SLR, we
chose to perform focused SLRs for each topic separately.
This resulted in 14 dedicated search strings (citations both
for induction and for maintenance treatments were
retrieved using the same search string). All study designs
were included (excluding narrative reviews, viewpoints, opi-
nion or consensus papers), with aminimum of 10 patients/
study (except in selected research questions with very lim-
ited data). The eligible studies were reviewed for snowball
references, and for each eligible study, data extraction con-
cerned parameters for all 15 research questions. A detailed
description of the search terms and strategy is provided in
online supplementary table 1, and the number of initial
articles retrieved and final articles included per research
question is shown in table 1.
The SLR was performed by three individuals (questions
1, 2, 7, 9: KC, questions 3, 6, 8, 10–15: AF, questions 4, 5:
MK), who independently screened all titles and abstracts
to identify studies that were eligible for full-text evaluation.
References from included studies were hand-searched to
consider any additional relevant articles. An independent
data extraction from included papers was performed and
evidence was summarised in dedicated tables, which were
formulated according to the research question. The level
of evidence (LoE) and strength of the recommendations
were graded according to the 2009 Oxford Centre for
Evidence-Based Medicine,5 based on the design and valid-
ity of available studies. Risk of bias (RoB)6 was assessed
using the Cochrane Risk of Bias Assessment Tool for RCTs
and the Newcastle-Ottawa scale for observational studies.7
The methodologist (GB) reviewed a random 20% of the
identified papers to resolve any disagreements in grading
of evidence. During the formulation and grading of
recommendations (GoR), the final LoE/GoR considered
the total body of evidence, including studies published
before 2012, as both the convenors (DJ, DTB), the meth-
odologist (GB) and several of the Task Force members
had also participated in the 2012 recommendations. An
overall detailed description of the results of the SLR is
shown in online supplementary table 2.
RESULTS
Predictive value of baseline clinical and histologic parameters
for long-term outcomes in lupus nephritis
The SLR identified that, at the time of LN diagnosis, (i)
compromised kidney function,21–28 (ii) hypertension27 29
and (iii) increased patient age30–32 have been associated
with adverse long-term kidney outcomes. With regard to
histologic features, proliferative forms of LN (histologic
classes III and IV according to the 2003 International
Society of Nephrology/Renal Pathology Society (ISN/
RPS) classification), increasing percentage of crescents
and higher National Institutes of Health histologic activ-
ity and chronicity scores have all been associated with
adverse long-term kidney outcomes. These associations
were confirmed in observational studies captured in the
current SLR.31 33–39 However, from the latter, it became
evident that additional histologic features may also carry
prognostic implications. Specifically, tubulointerstitial
lesions, especially interstitial fibrosis, tubular atrophy or
their combination, have been associated with increased
risk of ESKD or a composite outcome, in retrospective
observational studies.38 40–42 In a retrospective study of
105 patients with initial renal biopsy between 1987 and
2011 and a 10-year follow-up, presence of interstitial fibro-
sis/tubular atrophy in >25% of biopsy area was associated
with an almost fourfold increased risk for ESKD (HR:
3.89, 95% CI 1.25 to 12.14).43 Additionally, evidence of
thrombotic microangiopathy may be present in 5–25% of
patients with LN. Nevertheless, data from observational
studies regarding its impact on prognosis are equivocal;
six studies have shown association of thrombotic micro-
angiopathy with poor long-term renal outcomes (OR ran-
ging from 2.14 to 5.80) or worse response to
treatment,44–49 while five studies have failed to show
such an association.50–54
Hydroxychloroquine in lupus nephritis
Adetailed SLR concerning the efficacy and safety of hydro-
xychloroquine (HCQ) was performed in the context of
the recently updated EULAR recommendations for the
management of SLE.55 Consequently, the current SLR
focused on publications exploring the associations of
RMD Open
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HCQ specifically with LN outcomes; few such data are
available. In individual studies, use of HCQ has been asso-
ciated with a lower risk for tubulointerstitial inflammation
on kidney biopsy56 and with a higher likelihood for com-
plete response at 1 year.57 Regarding long-term outcomes,
HCQ use has been associated with reduced risk for ESKD/
chronic kidney disease (CKD) or doubling of serum crea-
tinine (adjustedHR0.18–0.40);27 58 59 a posthoc analysis of
the Aspreva Lupus Management Study (ALMS) RCT
showed that lack of treatment with antimalarials had
more than double risk for treatment failure (defined as
death or ESKD or sustained doubling of serum creatinine
or renal flare or requirement for rescue therapy) during
the maintenance phase (OR 2.4, p = 0.02).60 Data regard-
ing protection from kidney flares are equivocal61 62;
a single study showed lower blood concentrations of
HCQ in patients with LN who experienced a flare (0.59
vs 0.81mg/L; p = 0.005).63
Initial (‘induction’) therapies for lupus nephritis and efficacy of
calcineurin inhibitors in LN
The SLR identified 13 RCT comparing different regi-
mens for the initial treatment of LN (table 2 and
assessment of RoB of individual studies in online supple
mentary table 3).
With the exception of the LUNAR trial of rituximab
(RTX) in LN, and a recent multicenter phase II RCT
testing two doses of the calcineurin inhibitor (CNI)
voclosporin, which were both of low RoB, the remaining
studies had a higher RoB mainly due to deviations from
the intended interventions (blinding) or concerns over
the randomisation process (allocation sequence genera-
tion and concealment) (table 2). Importantly, five studies
compared the two main agents for LN, mycophenolate
mofetil (MMF) and cyclophosphamide (CY) (high-dose
regimen in three, low dose in one and both regimens in
one study), and none found superiority of one regimen
over the other. In the LUNAR trial, 144 racially diverse
patients with class III–IV LN were randomised to RTX or
placebo, together with glucocorticoids and MMF. The
study’s primary endpoint (complete remission at
52 weeks) was not met, as 26.4% in the RTX versus
30.6% in the placebo group achieved a complete remis-
sion at 52 weeks.15 Seven observational studies (two in
pediatric LN) reported on long-term (>3 years) outcomes
of patients treated with either CY or MMF as initial
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treatment. Although there was a marked heterogeneity
between studies (different maintenance treatments and
duration of follow-up), the majority of studies did not
show any difference in adverse renal outcomes.26 31 66–70
However, in a posthoc analysis of the ALMS trial, initial
treatment with CY was associated with a lower likelihood
of treatment failure (OR 0.5, p = 0.05).60
Regarding the use of CNI in LN, the majority of studies
(RCT and observational) have used tacrolimus (TAC),
rather than ciclosporin A (online supplementary table
2, sections 4.1.3 and 4.1.4). CNI (either alone or in com-
bination with MMF) were at least as efficacious as stan-
dard of care in a number of RCTs; however, the
robustness of evidence is limited as many studies were
subject to moderate/high RoB (mostly due to deviations
from the intended interventions). A multicenter RCT
compared the ‘multitarget’ therapy (TAC 4 mg/day +
MMF 1 g/day) against monthly pulses CY (0.5–1 g/m2)
for induction therapy in 362 Chinese patients with new-
onset LN. Both regimens were combined with glucocorti-
coids. At 6 months, complete renal response rates were
45.9% with the MMF/TAC combination versus 25.6%
with CY (p < 0.001).19 Mok et al published a RCT in 150
Chinese patients with classes III–IV (81%) or pure class
V (19%) LN, who were randomised to either TAC
(0.06–0.1 mg/kg/day) or MMF (2–3 g/day), in a back-
ground of prednisone (0.6 mg/kg/day). At 6 months,
complete renal response was achieved by 59% of patients
in the MMF and 62% of patients in the TAC group
(p = 0.71).16 During maintenance with azathioprine
(AZA), proteinuric and nephritic flares developed in
24% of patients and 18% of patients in the MMF group,
and 35% (p = 0.12) and 27% (p = 0.21) in the TAC group,
respectively. Finally, in the aforementioned phase II RCT
comparing two doses of voclosporin in combination to
MMF versus MMF alone, the rate of complete response at
48 weeks was significantly higher for both voclosporin
groups over MMF alone (OR 3.21, p < 0.001 and 2.10,
p = 0.02 for low dose and high dose, respectively, low
RoB).20 Phase III data of voclosporin announced positive
results following the completion of the SLR, but the full
study has not yet been published.71
For class V LN, we found only one small RCT (n = 16)
that included exclusively patients with class V, in which
MMF was better than TAC in terms of complete renal
response (high RoB).17 A network meta-analysis of 206
patients with class V did not find any difference in renal
response or reduction of proteinuria between various
treatments (including CNI and MMF).72 Regarding mul-
titarget treatment, a meta-analysis of 8 trials that com-
pared TAC + MMF versus CY showed superior efficacy of
the former in class V (response rate (RR): 4.24,
p = 0.02).73
No controlled studies have compared different gluco-
corticoid regimens in the initial phase of LN. Table 3
shows the glucocorticoid tapering schemes of major
RCT in LN over the period 2012–2018. Regarding non-
controlled studies, a retrospective observational study in
two different centres showed that, following initial pulse
intravenous methylprednisolone, a lower starting dose of
glucocorticoids (≤0.5 mg/kg/day) was as efficacious as
a higher dose.74 In the RITUXILUP observational study,
a single RTX dose, combined with MMF and methylpred-
nisolone pulses, and no oral glucocorticoids, was accom-
panied by high rates of complete/partial response (90%,
45/50 patients) after median 37 weeks.75
Subsequent (‘maintenance’) therapies for lupus nephritis
We found three RCTs specifically designed to compare
different treatment regimens for the maintenance ther-
apy in LN (table 4 and assessment of RoB of individual
studies in online supplementary table 3). Chen et al






No 20–25 mg/day for 2 weeks To 2.5 mg/day at week 16
Rathi, 2016 (MMF vs
low-dose CY)10
3 × 750 mg 1 mg/kg/day for 8 weeks Not specified
Mok, 2015 (MMF vs
TAC)16
No 0.6 mg/kg/day for 6 weeks By 5 mg/day every week to <10 mg/day, then indefinitely
Liu, 2014 (multitarget
vs CY)19
3 × 500 mg 0.6 mg/kg/day for 4 weeks By 5 mg/day every 2 weeks to 20 mg/day, then by 2.5 mg/
day every 2 weeks to 10 mg/day
Furie 2014
(abatacept)64
No 30–60 mg/day To 10 mg/day by week 12 recommended
Askanase, 2014
(abatacept)65
Optional 60 mg/day for 2 weeks To 10 mg/day by week 10
Rovin, 2012 (RTX)15 3 × 1000 mg 0.75 mg/kg/day (max.
60 mg) until day 16
To 10 mg/day by week 16
CY, cyclophosphamide; IV-MP, intravenous methylprednisolone; LN, lupus nephritis; MMF, mycophenolate mofetil; MP, methylprednisolone;
PO, per os; RCT, randomised controlled trial; RTX, rituximab; TAC, tacrolimus.
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randomised 70 patients to either TAC or AZA following
induction; relapse rate did not differ at 24 weeks (OR for
relapse of AZA vs TAC: 1.06, p = 0.49), with some con-
cerns regarding RoB.76 In a smaller study, also in an Asian
population, Yap et al compared TAC to MMF in 16
patients; primary endpoint was proteinuria, serum albu-
min and creatinine at 106 weeks and no differences were
found between arms (high RoB).17 Another RCT com-
pared the efficacy of MMF with AZA in 81 patients with
proliferative disease who were previously treated with
CY.77 At 36 months, both the event-free survival rate for
the composite endpoint of death or ESKD and the
relapse-free survival rate were comparable between arms
(95.1% with MMF vs 91.3% with AZA, p = 0.31 and 90.2%
with MMF vs 85% with AZA, p = 0.45, respectively).
In addition, the 10-year results of the MAINTAIN trial
(AZA vsmycophenolic acid (MPA) formaintenance treat-
ment of LN) represent extended data of a previous
RCT.78 Over 10 years, the two groups experienced similar
results in terms of renal flares (45% with MPA, 49% with
AZA) and ESKD (7.1% with MPA, 2.2% with AZA). AZA/
MPA switch occurred in 20% and 14% of AZA and MPA
patients, respectively (RoB ‘some concerns’). Addition-
ally, the aforementioned Chinese RCT of ‘multitarget’
therapy for LN19 also performed a study on subsequent
treatment following induction, comparing TAC/MMF
combination to AZA.79 In this study, 206 patients were
randomised to either MMF+TAC (n = 116) or AZA
(n = 90), following the same randomisation with the
original induction study. At 18 months, no difference in
relapse rates was found between the two arms (5.5% in
themultitarget vs 7.6% in the AZA, adj. HR: 0.82, p = 0.7).
Finally, a favourable effect of MMF over AZA on renal
relapse rates has been reported in two meta-analyses
(including one network meta-analysis), involving mostly
Asian and/or African American populations, and includ-
ing trials published before the initiation date of the cur-
rent SLR.80 81
Monitoring of lupus nephritis and targets of therapy
The SLR focused on the usefulness of common laboratory
tests (serological and urinary) tomonitor LN, rather than
on various investigational biomarkers that have been used
in research studies. In this context, proteinuria and
serum creatinine were found to be strongly associated
with long-term kidney outcomes. Posthoc analyses of
RCT and observational studies have shown that reduc-
tions in proteinuria within the first 3, 6 or 12 months
are associated with favourable long-term outcomes in
LN (table 5 and online supplementary table 4).
Posthoc data from the MAINTAIN and Euro-Lupus
Nephritis trials (ELNT) showed that proteinuria values
0.7 and 0.8 gr/day, respectively, had the best predictive
value for a serum creatinine <1.0 mg/dL at 7 years.82 83
This was confirmed in the large Lupus Nephritis Trials
Network (LNTN) surrogate marker study which found
that higher levels of proteinuria at 12 months conferred
a greater risk for CKD, severe kidney injury in both pro-
liferative and membranous LN, and for kidney replace-
ment therapy.85 Similar results were yielded for serum
creatinine at 1 year in the same studies. On the contrary,
addition of hematuria to proteinuria and/or serum crea-
tinine not only did not improve, but in some instances
decreased the sensitivity of risk models to predict adverse
long-term outcomes in LN, in data analysis from ELNT,
MAINTAIN, ALMS as well as the LNTN surrogate marker
study.
Role of repeat kidney biopsy in lupus nephritis
A total of 26 observational studies since 2012 have evalu-
ated repeat kidney biopsy, performed either per protocol
or during an LN flare (online supplementary table 2,
section 6.4). Regarding histological transition, the major-
ity of patients with class II (75–80%) progress to class III, IV
or V; of patients with class V, 33–43% show histological
transition, mostly to proliferative forms. On the contrary,
70–80% of patients with proliferative or mixed classes
Table 4 Randomised trials of subsequent (‘maintenance’) therapy in lupus nephritis











TAC + P AZA + P 10 mg/d 24 w
relapse





Yap et al17 16
(1:1)
TAC + P MMF + P 5–7.5 mg/d 106 w,
proteinuria,
Alb, sCr












rate MMF vs AZA: 95.1% vs
91.3%, p = 0.31
Some
concerns
*Overall risk of bias was assessed using the Revised Cochrane risk-of-bias tool (ROB2).
AZA, azathioprine; Alb, albumin; d, days; ESRD, end-stage renal disease; MMF, mycophenolate mofetil; P, prednisone; sCr Serum creatinine;
TAC, tacrolimus; w, weeks.
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remain in proliferative classes. On average, repeat biopsy
leads to change in immunosuppressive treatment in >50%
ofpatients (intensification in 70–95%, reduction in 5–30%).
Notably, there is often discordance between clinical and
histological remission; in one study with 25 repeat biopsies,
60% of patients with an activity index of 0 had residual
proteinuria >500mg/day, while 30%of thosewith complete
clinical response had an activity index >5 in the repeat
biopsy.68 In the Lupus Flares andHistological Renal Activity
at the End of the Treatment (LuFla) prospective study, 36
patients who had received ≥36 months of immunosuppres-
sion and were in complete response for ≥12 months under-
went re-biopsy and subsequent therapy discontinuation; of
the 11 patients who flared over the next 2 years, 10 had
residual histologic activity in the repeat kidney biopsy.86
Duration of immunosuppressive treatment in lupus nephritis
No RCTs have compared different durations of immuno-
suppressive/biologic treatment in LN and observational
data are also limited. In a small RCT, 15 patients with LN
and at least partial remission were randomised to either
continueordiscontinueglucocorticoids.87Over36months,
4/8 on glucocorticoid continuation exhibited flares com-
pared to 1/7 (14%) in glucocorticoid (GC) withdrawal
group (HR: 2.68, p > 0.05). In a single retrospective obser-
vational study, immunosuppressive therapy was discontin-
ued in 73 patients who had received median 73 months of
therapy; 38% experienced flares at median 3 years follow-
ing treatment discontinuation. Longer duration of treat-
ment (98 vs 31 months) and longer duration of remission
(52.8 vs 12months) before interruptionwas associated with
a lower risk of flare occurrence.88 Finally, open-label exten-
sions of RCT and observational studies suggest that the
majority of kidney flares tend to occur within the first
5–6 years of therapy; after this point, their rate decreases
significantly but does not reach zero.34 62 78 89 90
Treatment of refractory lupus nephritis
Available randomised and observational studies regard-
ing the efficacy of different treatments in refractory or
relapsing LN are shown in table 6 (and assessment of RoB
of individual studies in online supplementary table 3).
A randomised trial comparing CY to mycophenolate
sodium in 59 Asian patients showed comparable rates of
remission at 12 months (68 vs 70.9%), but the study was
prematurely terminated due to more serious adverse
events in the CY arm.91 Another RCT compared the com-
bination of RTX with CY to CY alone in 84 Chinese
patients for 12 months; rate of combined complete and
partial remission was higher in the RTX/CY combination
arm (83.3% vs 57.1%, p < 0.05).96 The efficacy of RTX has
also been tested in various prospective and retrospective
observational studies. Overall response rate varies
between 53% and 94.1%, and relapse rates vary between
24% and 45% (table 6). MMF has been tested in a single
retrospective observational study of 85 patients with
refractory LN, previously treated with CY. During a follow-
up of 5 years, partial and complete remission was
achieved in 60% and 27%, respectively, while 5.8% of
patients had progressed to ESKD.102 Finally, in a pooled
posthoc analysis of the BLISS trials, belimumab has
shown antiproteinuric effect and fewer renal relapses in
a mixed new-onset and refractory LN population.103
More recently, a phase III RCT of belimumab compared
to placebo (both combined with standard of care) in LN
announced positive results meeting its primary endpoint
(renal response in 2 years); however, the results of the
trial are yet to be published.104
Management of end-stage kidney disease in lupus nephritis
A meta-analysis of 187 articles and a total of 18 309
patients reported that the 5-year risk of ESKD in devel-
oped countries decreased from 16% in the period
1970–1979 to 11% in the mid-1990s, showing
a plateau thereafter.105 The risk of ESKD in develop-
ing countries was higher. After reaching ESKD, all
methods of kidney replacement therapy (haemodialy-
sis (HD), peritoneal dialysis (PD) and kidney trans-
plantation (KT)) can be used in patients with LN.
A study using data from the United States Renal Data
Table 5 Performance of different proteinuria cut-off values to predict long-term outcomes in individual studies
Reference
Cut-off and
timepoint Sensitivity Specificity PPV NPV Outcome
Dall’Era, 2015 (ELNT)82 0.8 gr at 12 months 81% 78% 88% 67% sCr ≤1 at 7 years
Tamirou, 2015
(MAINTAIN)83
0.7 gr at 12 months 71% 75% 94% 29% sCr ≤1 at 7 years
Tamirou, 2016
(MAINTAIN)78






sCr ≤120% baseline at
10 years
Dall’Era, 2015 (ALMS)60 1 gr at 6 months NR NR NR NR OR 0.3 for CR during
maintenance
Ugolini-Lopes, 201784 0.8 gr at 12 months 90% 78% 67% 94% sCr ≤1.5 at 7 years
Yang, 201521 1.2 gr (time-
adjusted)
92.1% 83.9% NR NR ESKD
ALMS, Aspreva Lupus Management Study; CR, complete response; ELNT, Euro-Lupus Nephritis Trial; ESKD, end-stage kidney disease; NPV,
negative predictive value; NR, not reported; PPV, positive predictive value; sCr, serum creatinine.
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System (USRDS) on 11 317 LN patients reported that
82.0% initiated HD, 12.2% initiated continuous PD
and only 2.8% underwent KT.106 We identified five
retrospective studies that have compared the three
modalities, as regards to patient outcomes in LN
(online supplementary table 5).107–111 In three studies,
HD was compared to continuous PD, while in two
additional studies,108 111 a KT arm was also included.
In the studies comparing HD to PD, no difference was
found in overall patient survival; in the two studies that
included a KT arm, the latter was found to be asso-
ciated with higher patient survival rates at 1, 5 and
10 years. Recent data from the USRDS comparing LN-
ESKD patients who underwent transplantation versus
those who did not (total 9659 patients) showed a 70%
reduction in all-cause mortality (adj. HR: 0.30, 95% CI
0.27 to 0.33), along with reductions in cause-specific
mortality (CVD, infections, sepsis, etc).112
Cardiovascular risk and risk for infections in patients with
lupus nephritis
Similar to the question onHCQ, a focused SLR regarding
infections and cardiovascular disease (CVD) in general
SLE was performed in the context of the EULAR recom-
mendations for the management of SLE.55 The current
SLR focused on publications exploring the associations of
Table 6 Efficacy of different therapeutic agents in refractory/non-responding or flaring LN
Reference
Type of
















CR+PR: CY vs EC-MPS 68%
vs 71%, p = ns
TF: CY vs EC-MPS 46.9% vs
37%, p = ns
Premature termination due to
high rate of serious adverse
events in CY arm
High
Moroni et al92 Observational CY:14
RTX:10
PO CY + P RTX + P 3y CR CR: CY vs RTX 92% vs 80% 7
Multitarget
Choi et al93 Observational 29 MMF + TAC
+ P
- 12 m CR, PR CR: 25.9%
PR: 29.6%
4
Mok et al94 Observational 21 MMF + TAC
+ P
- 12 m CR, PR CR+PR: 67% 5
Kasitanon
et al95
Observational 21 MMF + CsA
+ P add-on
to IS




Zhang et al96 RCT 84 (1:1) CY + RTX +
P
CY + P 12 m CR, PR CR+ PR: CY vs RTX+CY
57.1% vs 83.3% p < 0.05
High
Kotagiri et al97 Observational 14 RTX +
p add-on to
IS





Davies et al98 Observational 18 RTX + CY +
P







Observational 25 RTX + CY +
P













Contis et al101 Observational 17 RTX + P - 52 w CR, PR CR+PR: 53% 4
MMF






*Overall risk of bias was assessed using the Revised Cochrane risk-of-bias tool (ROB2) for RCT and the Newcastle-Ottawa scale for
observational studies.
CY, cyclophosphamide; CR, complete response; CsA, ciclosporin A; EC-MPS, enteric-coated mycophenolate sodium; IS,
immunosuppressant; m, months; MMF, mycophenolate mofetil; P, prednisone; PR, partial response; RCT, randomised controlled trial; RTX,
rituximab; TF, treatment failure; TAC, tacrolimus; w, weeks; y, years.
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these comorbidities specifically with LN. Both disease-
and treatment-related factors account for an increased
CVD risk in LN. A single meta-analysis correlated LN
with CVD (OR 1.6, 95% CI 1.04 to 2.60, although not
reporting clearly on the heterogeneity of reported
studies)113; however, a number of low-quality trials have
failed to prove a significant association. Similarly, contra-
dictory results were obtained from studies that used sur-
rogate CVD endpoints, such as subclinical
atherosclerosis.114–117 In the single prospective trial that
explored the possible atheroprotective effect of ACE inhi-
bitors and angiotensin receptor blockers in patients with
LN, there was no difference in the cumulative occurrence
of CVD between the treatment and the control arm
(p = 0.7).118 The increased risk for infections in patients
with LN is supported by a number of studies (HR: 1.4–-
5.3)119–122; regarding treatment-related risk factors,
a network meta-analysis of 32 RCTs identified that high-
dose GC therapy was associated with the highest risk for
serious infections compared to TAC as reference drug
(OR 12.8, 95% CI 1.53 to 119.90), followed by low-dose
CY (OR 4.8, 95% CI 1.48 to 17.64) and high-dose CY (OR
6.6, 95% 2.25 to 20.50).123
DISCUSSION
Kidney involvement in SLE has significant implications
for the disease management and prognosis. Several
authorities, including the Kidney Disease Improving Glo-
bal Outcomes (KDIGO) and American College of Rheu-
matology, have published recommendations for the
management of LN.124 The recently published update
of the joint EULAR/ERA-EDTA recommendations was
based on a dedicated SLR, which covered several aspects
of the disease (formed in the 15 research questions) and
not just the efficacy and safety of immunosuppressive
agents used in the treatment of its different phases. To
this end, we followed an inclusive approach during article
selection, in order to capture data from observational and
non-controlled studies, in topics where randomised con-
trolled studies are absent or scarce. Importantly, because
this was an update of previous recommendations pub-
lished in 2012,2 data retrieval started from the ending
date of the previous SLR, although overall LoE and GoR
took into account the whole body of evidence.
Kidney biopsy remains a cornerstone in the diagnosis
and management of LN, because the prognostic value of
histological findings cannot be replaced by any clinical or
laboratory parameter. In addition to features with well-
established prognostic value (histological class, activity
and chronicity indices, presence of crescents), from the
review of the literature it became evident that acute or
chronic lesions of the tubulointerstitial space (inflamma-
tion and fibrosis/tubular atrophy, respectively) are also
associated with adverse short- and long-term outcomes.
Regarding features of thrombotic microangiopathy,
prognostic associations are more equivocal, despite the
fact that such lesions may be present in up to one in four
kidney biopsies in LN. A current revision of the 2003 ISN/
RPS class, which will address these issues, is currently
under way. The issue of repeat kidney biopsy, performed
either per protocol or during a disease flare, was explored
in several observational studies; histological transition is
common, often leading to changes in treatment.
Regarding management of LN, our SLR confirmed the
equal efficacy of MMF and CY for the initial (‘induction’)
phase of LN, as evidenced by a number of RCTs in differ-
ent ethnic/racial groups, whichwas recently suggested also
by a Cochrane systematic review.80 Importantly, the low-
doseCY regimen (ELNT)was tested also in non-exclusively
Caucasian populations, with similar results.10 13 14 65
Regarding the use of CNI or ‘multitarget’ therapy (combi-
nation of CNI with MMF), it is important to point out that
the majority of studies (both randomised and observa-
tional) testing this class of drugs have used TAC, hence
the respective clarification in the manuscript of the
updated EULAR/ERA-EDTA recommendations.55 The
scepticism raised by the fact that initial studies using the
multitarget regimen were performed in Asian populations
has been partly addressed by the multi-ethnic phase II
study of voclosporin/MMF combination20; the results of
the phase III study, which recently announced positive
results, are expected to provide more data regarding
a possible future universal recommendation ofmultitarget
regimens for LN.
A GC dosing regimen pointing towards lower cumulative
GC doses was suggested in the recommendations, stating
that ‘the use of IV pulses methylprednisolone (total dose
500–2500 mg, depending on disease severity) is recom-
mended, followed by oral prednisone (0.3–0.5 mg/kg/
day) for up to 4 weeks, tapered to ≤7.5 mg/day by 3 to
6 months’. Unfortunately, there is a paucity of RCTs that
have directly compared different glucocorticoid regimens
in LN. Apart from the uncontrolled studies mentioned in
the “Results” section, the older open-label, controlled
MyLupus study (not included in the current SLR) had
shown that lower CG doses with enteric-coated mycophe-
nolate sodium were accompanied by similar rates of com-
plete response at 24 weeks.125 Importantly, the need to
minimise the use of GC in general SLE was also empha-
sised in the 2019 updated EULAR recommendations for
the management in SLE.55 Ultimately, despite the lack of
robust data, the current recommendations attempt to
adapt to the current trend in SLE therapeutics, towards
a rationalisation of GC use, with concurrent capitalisation
of potent immunosuppressive agents.126
In terms of monitoring of LN, a number of posthoc
analyses of major studies in LN suggested the value of an
early proteinuria response, together with a normal serum
creatinine, within 12 months, to predict a favourable long-
term outcome of patients.60 82–85 By contrast, glomerular
haematuria was consistently shown in the same studies to
add no predictive value in these prognostic models.
Although these findings may not necessarily impact rou-
tine clinical practice, where urine microscopy will con-
tinue to be part of patient monitoring, however, they
RMD Open
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may well carry implications regarding future design of
optimal endpoints for clinical trials. Haematuria may be
particularly persistent to immunosuppressive treatment;
its omission from the components of a ‘clinical response’,
owing to its poor prognostic value, may allow more clinical
trials of drugs under investigation to reach their target.127
Facing a flare or prior to labelling a patient with LN as
‘refractory to treatment’, a thorough investigation of
possible causes is mandatory. In this regard, assessment
of adherence to treatment is of utmost importance;
suboptimal compliance rates, especially with HCQ,
have been documented in SLE and may correlate with
LN flares.128
In summary, the SLR that supported the update of
the joint EULAR/ERA-EDTA recommendations found
a high quality of data regarding induction and main-
tenance treatments in the management of LN, but
low-to-moderate quality concerning most other aspects
of this disease. Issues like long-term efficacy and safety
of novel treatment regimens, optimal duration of
immunosuppressive therapy after patients reach remis-
sion or the role of repeat kidney biopsy need to be
further explored.
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